Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

Now more than ever is the time of monoclonal antibody use in neurology. In headaches, disease-specific and mechanism-based treatments existed only for symptomatic management of migraines (i.e., triptans), while the standard prophylactic anti-migraine treatments consist of non-specific and repurposed...

Full description

Bibliographic Details
Main Authors: Theodoros Mavridis, Christina I. Deligianni, Georgios Karagiorgis, Ariadne Daponte, Marianthi Breza, Dimos D. Mitsikostas
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
calcitonin gene-related peptide
CGRP
erenumab
fremanezumab
galcanezumab
eptinezumab
Online Access:https://www.mdpi.com/1424-8247/14/7/700

Similar Items

Similar Items